Sonepcizumab shows promise for metastatic kidney cancer

Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). However, despite the modest PFS (mean of 2.2 months), the encouraging overall survival warrant further investigation of sonepcizumab in combination with immunotherapies and vascular endothelial growth factor (VEGF) inhibitors. Read more here